• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索钙调磷酸酶抑制剂-free 维持免疫抑制的肝移植受者中可预测的间接可识别 HLA 表位 (PIRCHE-II)。一项回顾性单中心研究。

Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study.

机构信息

CHU Saint Eloi, Hepatology and Liver transplantation unit, Montpellier, France.

PIRCHE AG, Berlin, Germany.

出版信息

Transpl Immunol. 2020 Apr;59:101272. doi: 10.1016/j.trim.2020.101272. Epub 2020 Feb 12.

DOI:10.1016/j.trim.2020.101272
PMID:32061667
Abstract

The PIRCHE (Predicted Indirectly ReCognizable HLA Epitopes) score is an HLA epitope matching algorithm. PIRCHE algorithm estimates the level of presence of T-cell epitopes in mismatched HLA. The PIRCHE-II numbers associate with de novo donor-specific antibody (dnDSA) formation following liver transplantation and kidney allograft survival following renal transplantation. The aim of our study was to assess the PIRCHE-II score in calcineurin inhibitor (CNI)-free maintenance immunosuppression recipients. This was a retrospective study of forty-one liver transplant recipients on CNI-free immunosuppression and with available liver allograft biopsies. Donors and recipients were HLA typed. The HLA-derived mismatched peptide epitopes that could be presented by the recipient's HLA-DRB1 molecules were calculated using PIRCHE-II algorithm. The associations between PIRCHE-II scores and graft immune-mediated events were assessed using receiver operating characteristics curves and subsequent univariate and multivariate analyses. CNI-free patients with cellular rejection, humoral rejection, or severe portal inflammation had higher mean PIRCHE-II scores compared to patients with normal liver allografts. PIRCHE-II score and donor age were independent risk factors for liver graft survival in CNI-free patients (HR: 8.0, 95% CI: 1.3-49, p = .02; and HR: 0.88, 95% CI: 0.00-0.96, p = .007, respectively). PIRCHE-II scores could be predictive of liver allograft survival in CNI-free patients following liver transplantation. Larger studies are needed to confirm these results.

摘要

PIRCHE(预测间接可识别 HLA 表位)评分是一种 HLA 表位匹配算法。PIRCHE 算法估计错配 HLA 中 T 细胞表位的存在水平。PIRCHE-II 数字与肝移植后新的供体特异性抗体(dnDSA)形成和肾移植后肾移植物存活有关。我们的研究目的是评估钙调神经磷酸酶抑制剂(CNI)免费维持免疫抑制治疗患者的 PIRCHE-II 评分。这是一项对 41 名接受 CNI 免费免疫抑制治疗且有可用肝移植活检的肝移植受者的回顾性研究。对供体和受者进行 HLA 分型。使用 PIRCHE-II 算法计算可以由受者 HLA-DRB1 分子呈递的 HLA 衍生错配肽表位。使用接收者操作特性曲线和随后的单变量和多变量分析评估 PIRCHE-II 评分与移植物免疫介导事件之间的关联。与具有正常肝移植物的患者相比,发生细胞性排斥反应、体液性排斥反应或严重门脉炎症的 CNI 免费患者的平均 PIRCHE-II 评分更高。PIRCHE-II 评分和供体年龄是 CNI 免费患者肝移植物存活的独立危险因素(HR:8.0,95%CI:1.3-49,p=0.02;和 HR:0.88,95%CI:0.00-0.96,p=0.007)。PIRCHE-II 评分可预测 CNI 免费患者肝移植后的肝移植物存活。需要更大的研究来证实这些结果。

相似文献

1
Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study.探索钙调磷酸酶抑制剂-free 维持免疫抑制的肝移植受者中可预测的间接可识别 HLA 表位 (PIRCHE-II)。一项回顾性单中心研究。
Transpl Immunol. 2020 Apr;59:101272. doi: 10.1016/j.trim.2020.101272. Epub 2020 Feb 12.
2
Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.基于预测的间接可识别 HLA 表位的供受者匹配独立预测肾移植后新出现的供者特异性 HLA 抗体的发生率。
Am J Transplant. 2017 Dec;17(12):3076-3086. doi: 10.1111/ajt.14393. Epub 2017 Jul 28.
3
Can PIRCHE-II Matching Outmatch Traditional HLA Matching?PIRCHE-II 配型能否优于传统 HLA 配型?
Front Immunol. 2021 Feb 26;12:631246. doi: 10.3389/fimmu.2021.631246. eCollection 2021.
4
Association between PIRCHE-II scores and de novo allosensitization after reduction of immunosuppression during SARS-CoV-2 infection in kidney transplant recipients.新型冠状病毒感染期间降低免疫抑制剂治疗后肾移植受者 PIRCHE-II 评分与新生同种异体致敏的相关性。
Transpl Infect Dis. 2023 Apr;25(2):e14052. doi: 10.1111/tid.14052. Epub 2023 Mar 8.
5
Predictive value of HLAMatchmaker and PIRCHE-II scores for de novo donor-specific antibody formation after adult and pediatric liver transplantation.HLAMatchmaker 和 PIRCHE-II 评分对成人和儿童肝移植后新出现的供体特异性抗体形成的预测价值。
Transpl Immunol. 2020 Aug;61:101306. doi: 10.1016/j.trim.2020.101306. Epub 2020 May 16.
6
Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.钙调磷酸酶抑制剂免抑治疗对肝移植受者体内新型供者特异性抗体形成的影响。
Liver Int. 2022 May;42(5):1132-1143. doi: 10.1111/liv.15201. Epub 2022 Mar 1.
7
PIRCHE-II Is Related to Graft Failure after Kidney Transplantation.PIRCHE-II 与肾移植后移植物失功相关。
Front Immunol. 2018 Mar 5;9:321. doi: 10.3389/fimmu.2018.00321. eCollection 2018.
8
Analysis of T and B Cell Epitopes to Predict the Risk of Donor-Specific Antibody (DSA) Production After Kidney Transplantation: A Two-Center Retrospective Cohort Study.分析T细胞和B细胞表位以预测肾移植后供体特异性抗体(DSA)产生的风险:一项双中心回顾性队列研究。
Front Immunol. 2020 Aug 27;11:2000. doi: 10.3389/fimmu.2020.02000. eCollection 2020.
9
Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.移植肾后预测 HLA 细胞毒性 T 细胞表位靶点与 T 细胞介导排斥反应的关系。
Am J Kidney Dis. 2022 Dec;80(6):718-729.e1. doi: 10.1053/j.ajkd.2022.04.009. Epub 2022 Jun 9.
10
Association of HLA B- and T-cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation.HLA 分子错配与 HLA 抗体、排斥反应和儿童肾移植中移植物存活的关系。
Pediatr Transplant. 2024 Aug;28(5):e14773. doi: 10.1111/petr.14773.

引用本文的文献

1
Understanding HLA-DQ in renal transplantation: a mini-review.肾移植中对人类白细胞抗原-DQ的理解:一篇综述短文
Front Immunol. 2025 Feb 5;16:1525306. doi: 10.3389/fimmu.2025.1525306. eCollection 2025.
2
Improving long-term kidney allograft survival by rethinking HLA compatibility: from molecular matching to non-HLA genes.通过重新思考HLA相容性提高肾移植长期存活率:从分子匹配到非HLA基因
Front Genet. 2024 Oct 2;15:1442018. doi: 10.3389/fgene.2024.1442018. eCollection 2024.
3
Immunology of simultaneous liver and kidney transplants with identification and prevention of rejection.
肝肾联合移植的免疫学:排斥反应的识别与预防
Front Transplant. 2022 Nov 1;1:991546. doi: 10.3389/frtra.2022.991546. eCollection 2022.